Frechen (pta010/25.08.2020/08:00) - * Dataset with over 3 million graded retinal images
* Validated using clinical trial standards
* Active public marketing started with its own website
* Interest on the part of research and industry in optimizing diagnostics and therapy
With the advancing digitization in the healthcare sector and the use of artificial intelligence (AI), data becomes increasingly important. They enable completely new approaches in diagnostics and therapy. This is particularly relevant in ophthalmology, because the standardized evaluation of images, that are made during the examinations, provides valuable information about the most promising approaches to therapy. ifa systems AG provides even more support currently and in the future.
Inoveon Corp, an American subsidiary of ifa systems AG, has developed a dataset of over 3 million anonymized and clinical trial (ETDRS) qualified images in the field of ophthalmology. This dataset is now being offered to institutions from research and industry for use. The website www.accuretina.com was created for this purpose, which provides information on the possible uses.
"Patients with diabetes in particular have an increased risk of going blind," says Jörg Polis, chairman of the board of ifa systems AG. "By comparing current retinal images with artificial intelligence garnered from ifa's extensive referenced retinal dataset, this risk can be identified early and counteracted accordingly. The automated evaluation can thus provide concrete protection against loss of vision."
Companies from research and industry can use this dataset for a license fee. The anonymized and searchable dataset consist of 7-field stereo retinal images that were recorded in a clinical environment, with structured demographic patient data including patient progression data, of structured reading data using the reference standard protocol ETDRS (Early Treatment Diabetic Retinopathy) and from structured grading including ETDRS level, macular edema levels and identification of other pathologies. The dataset has extensive quality assurance features, including random (10%) intra- and interreader overreads under the supervision of a retinal specialist.
Contact for questions:
ifa systems AG
+49 2234 933 670
With over 30 years of experience, ifa systems AG is one of the world's leading providers of software solutions in ophthalmology. The focus of the company's activities is on the development of an electronic patient record (EPA) tailored to the needs of ophthalmology. ifa's EPA, in which all details of examinations and treatments are documented and managed, can be flexibly used in specialist practices and eye centers as well as in specialized departments of hospitals. In addition, the range of products also includes supplementary software products for linking up ophthalmological diagnostic devices to a network. With its innovative product portfolio, ifa makes a decisive contribution to ensuring the optimal treatment of patients and supports the simplification of procedures for doctors and medical staff. With the products and solutions of ifa systems AG, people in more than 20 countries worldwide work at more than 15,000 workplaces, managing more than 200,000 clinical patient cases every day. According to experts, this niche market will grow to a volume of over 6.2 billion US dollars by 2020. ifa systems AG is listed on the Open Market of the Frankfurt Stock Exchange with ISIN DE 007830788. NEXUS AG holds more than 50% of the shares and is also listed on the stock exchange (ISIN DE0005220909).
|emitter:||ifa systems AG|
Augustinusstraße 11 b
|contact person:||Thessa Roderig|
|phone:||+49 171 3108298|
|stock exchanges:||free market in Dusseldorf, basic board in Frankfurt, free market in Hamburg, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate|